John E. Bailye Previously, John Bailye founded, chaired and served as CEO of Dendrite, a pioneer in the development of software applications for pharmaceutical sales force management. Under his leadership, Dendrite grew from $175,000 in annual sales in 1987 to more than $420 million in 2006. The company received wide industry acclaim and was ranked 44 among the 100 fastest growing companies in the United States by Fortune Magazine in 2000. In May 2007, Dendrite was sold for nearly $800 million. At that time Dendrite was a publicly traded global company that employed nearly 3,000 people in approximately 60 countries, and its client base included the world’s top 20 pharmaceutical companies. Originally from Australia, John has been a leading supporter of entrepreneurship and technology growth in New Jersey, having served as a founding member of the New Jersey Technology Council. He received the Golden Door Award from the NJ International Institute and was twice honored with Ernst & Young's New Jersey Software and Technology Entrepreneur of the Year® award. In 2003, Business Review Weekly named him as one of the top 20 influential Australians in the United States. John is a graduate of the University of New South Wales. He holds a Bachelor of Commerce degree in finance, marketing, and business. Adele C. Oliva Adele Oliva joined Quaker BioVentures (www.quakerbio.com) as Partner in June 2007. Previously Adele was a Partner at Apax Partners which she joined in 1997 following her selection as a Ewing Marion Kauffman Fellow in Venture Capital and Entrepreneurship. At Apax, she co-led the Healthcare Group in the U.S. with a focus on specialty pharmaceuticals and medical devices/products. Prior to Apax, she held positions in marketing and business development with Baxter Healthcare in the company’s Cardiovascular and I.V. Systems divisions. Adele’s experience also includes positions with Ogilvy & Maher, where she was employed in the firm’s office in Hungary, and with CoreStates Financial Corp., where she worked as a commercial lending officer and senior financial analyst. In addition to EKR Therapeutics, her experience as a Board member includes Prometheus Labs, SkinMedica, Esprit Pharma, Alliance Healthcare Solutions, ESP Pharma., and Xanodyne Pharmaceuticals. Adele is a graduate of Saint Joseph’s University and earned an M.B.A. in Marketing from Cornell University, where she was awarded a Fried Fellowship. Scott A. Perricelli Scott is a Principal of LLR Partners (www.llrpartners.com) a Philadelphia-based private equity firm with $620 million of capital under management that focuses on investments in information technology, business services, healthcare and financial services enterprises. Scott has over twelve years of private equity investment and investment banking experience and possesses industry expertise in healthcare, information technology and outsourced business services. Prior to joining LLR Partners in 2001, Scott was a Principal at Draper Triangle Ventures, the Pennsylvania-based fund of Draper Fischer Jurvetson. Previously, he worked at Advanta Partners, a private equity firm affiliated with Advanta Corporation. Scott began his career in investment banking at William Blair & Company, where he advised emerging growth companies on a variety of investment banking transactions. Scott holds an M.B.A. in Finance and Entrepreneurship from the Kellogg School of Management at Northwestern University and B.S. in Accounting from Bucknell University Steven St. Peter, M.D. Dr. Steven St. Peter joined MPM Capital (www.mpmcapital.com) with experience from Apax Partners and The Carlyle Group, where his investment scope included both venture and buyout transactions across medical technology and pharmaceuticals. He began working at MPM in 2003 and was promoted to General Partner in 2005. Dr. St. Peter is board certified in internal medicine and was previously an assistant Clinical Professor of Medicine at Columbia University. He completed his Doctor of Medicine at Washington University and his residency and fellowship at the Hospital of the University of Pennsylvania. Prior to his medical training, he was an investment banker at Merrill Lynch. He also holds an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. in Chemistry from the University of Kansas. He is a Director of EKR Therapeutics, Helicos (NASDAQ: HLCS), Omrix (NASDAQ: OMRI), PharmAthene (ASE: PIP), Syndax, Xanodyne, and the New England Venture Capital Association, and previously served on the boards of Atugen and IDEA. Zev S. Scherl Zev Scherl is a General Partner at NewSpring Capital (www.newspringcapital.com), a family of private equity funds focused on the Mid-Atlantic region. He possesses significant experience in principal investing, corporate management and finance, focused exclusively in the life sciences and health care industries. Prior to NewSpring, he worked at Pequot Ventures where he orchestrated investments in emerging life sciences and health care companies. Previously, he was a member of the health care investment team of Behrman Capital where he originated, executed and actively managed health care investments. Before entering private equity in 1997, Zev served as Senior Director, Strategic Planning, for Value Health, the largest independent pharmacy and mental health benefit management company. He also served as U.S. Manager, Pricing Policy at Merck & Co., and prior to that was in the investment banking group at Lehman Brothers. In addition to serving as a Director for EKR Therapeutics, Mr. Scherl is currently a board member for AppTec Laboratory Services, Scandius BioMedical, Inc., Nitric BioTherapeutics, and Immune Control, Inc. He received a B.A degree with honors in economics from Duke University and an M.B.A. from Harvard Business School. S. Douglas Sheldon S. Douglas. Sheldon, a co-founder of EKR, is a co-founder and Managing Partner of ESP Equity Partners, LLC (www.espequity.com), a private equity fund with offices in New Jersey, Beijing and Bangkok. Previously, in 2000, Mr. Sheldon co-founded ESP Partners LLC, the predecessor to ESP Pharma, a specialty pharmaceutical company acquired by PDL BioPharma in 2005. He has over 30 years of pharmaceutical and related healthcare experience, both internationally and domestically, including having served as Vice-President of Strategic Partnership Development at Parke-Davis Pharmaceuticals. Doug began his career with Pfizer, Inc. where he served nearly 17 years in senior international finance, marketing, country management, and regional line management assignments in South America and Asia. He left Pfizer in 1991 to form TTMC, Ltd, a venture company focused on healthcare and life sciences businesses in South East Asia. Later, in 1994 he founded the Indochina Healthcare Ltd (IHL) joint venture operations in Thailand, Hong Kong, Vietnam and Myanmar, merging TTMC's hospital products business in orthopedics and urology with the oncology and cardiovascular business of Hospira Inc. (formerly Mayne Pharma). Today, he continues to actively serve as an Executive Director and Chairman of IHL. Mr. Sheldon, who is also fluent in Spanish, received his B.S. in Chemistry from LeMoyne College and M.B.A. in Finance and Marketing from Syracuse University. |
 |
|
|
|||||||||||||||
 |
|
|
|||||||||||||||
 |
 |
|
|||||||||||||||
| » About EKR Therapeutics |
| » Management |
| » Board of Directors |
| » Investor Relations |
| » Compliance Program |
| » Code of Conduct |
| » Contact EKR |
| » Directions |
Site Map | Privacy | Terms Of Use
©2010 EKR Therapeutics, Inc. All Rights Reserved.
Advancing Acute Care Therapeutics
